Physician profile
Michael K Cao
NPI 1548488877
$26,270.29
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $2,261 · 2021: $500 · 2022: $293 · 2023: $125 · 2024: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $281.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15,693.34 | 2019 | |
| Boston Scientific Corporation | $7,220.97 | 2019-2024 | Watchman Flx |
| Medtronic Vascular, INC. | $1,300.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,002.55 | 2019-2021 | |
| Galderma Laboratories, L.P. | $521.70 | 2019-2020 | |
| Amgen INC. | $167.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | Ofev |
| Sanofi-Aventis U.S. LLC | $58.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $35.70 | 2019 | |
| Radius Health, INC. | $35.00 | 2019 | |
| Gilead Sciences, INC. | $33.48 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.66 | 2019 | |
| Amarin Pharma, INC. | $23.62 | 2019 | |
| Pfizer INC. | $21.19 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.